Hangzhou Huasu Technology
301157
Zhejiang Chunhui Intelligent Control
300943
Ugreen Group Limited
301606
Zhengzhou Tiamaes Technology
300807
Shenzhen Dvision
300167
CN Stock MarketDetailed Quotes
002675 Yantai Dongcheng Biochemicals
- 12.15
- -0.24-1.94%
Noon Break Jan 7 11:30 CST
10.02BMarket Cap110.45P/E (TTM)
12.38High12.12Low28.96KlotVolume12.35Open12.39Pre Close35.36MTurnover0.39%Turnover Ratio47.83P/E (Static)824.60MShares18.2752wk High2.25P/B9.03BFloat Cap11.2852wk Low13.63Limit Up743.34MShs Float28.88Historical High11.15Limit Down2.10%Amplitude2.16Historical Low0.18Dividend TTM12.21Avg Price18.75KlotAsk1.44%Div YieldTTM100Lot Size9.58KlotBid
Yantai Dongcheng Biochemicals News
Optimism Around Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Delivering New Earnings Growth May Be Shrinking as Stock Declines 4.0% This Past Week
Yantai Dongcheng Biochemicals (002675.SZ) distribution of equity for the first three quarters: 0.5 yuan for every 10 shares.
Yantai Dongcheng Biochemicals (002675.SZ) announced that the company's equity distribution plan for the first three quarters of 2024 is as follows: based on public ...
Yantai Dongcheng Biochemicals (002675.SZ): Tosei Nuclear Medical received a government subsidy of 30 million yuan.
On December 10, Geelonghui reported that Yantai Dongcheng Biochemicals (002675.SZ) announced that recently, Dongcheng Nuclear Medical received government subsidy funds of 30 million yuan from the Finance Bureau of Yantai's Muping District.
zheshang Securities: Nuclear technology applications have wide downstream applications and enormous growth potential.
In 2022, the output value of non-power nuclear technology applications in our country accounted for approximately 0.57% of GDP, showing significant growth potential compared to developed countries overseas (which account for 2-3% of GDP).
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?
Deng Xiaofeng newly invested in a resource stock.
Private equity tycoons Feng Liu and Deng Xiaofeng's latest holdings are here! In the third quarter, Feng Liu's managed Gaoyi Linshan No. 1 Yuanwang Fund entered the top ten list of tradable shareholders of 10 A-share companies, with a total market cap of approximately 19.538 billion yuan. Specifically, in the third quarter, Feng Liu increased his holdings in Beijing Tongrentang, Yantai Dongcheng Biochemicals, and Jonjee Hi-Tech Industrial and Commercial Holding; reduced his holdings in Angel Yeast Co., Ltd. and Nanjing King-Friend Biochemical Pharmaceutical; maintained his position unchanged in Hangzhou Hikvision Digital Technology, LB Group Co., Ltd., Shengyi Technology, Xinxiang Richful Lube Additive, and Shanghai Titan Scientific Co., Ltd. Deng Xiaofeng's managed Gaoyi Xiaofeng No. 2 Fund entered the top ten list of tradable shareholders of 13 A-share companies in the third quarter, with a total market cap of approximately 7.917 billion yuan. Gaoyi Xiaofeng Hongyuan Fund
Private Equity tycoons Feng Liu and Deng Xiaofeng's latest heavy-holdings stocks are here!
Deng Xiaofeng is reducing holdings
Dongcheng Pharmaceutical Unit Receives 20 Million Yuan in Government Grants
Yantai Dongcheng Biochemicals (002675.SZ): A wholly-owned subsidiary has received a government subsidy of 20 million yuan.
Gelonghui November 5th | Yantai Dongcheng Biochemicals (002675.SZ) announced that on November 4, 2024, Dongcheng Medical received a government subsidy of 20 million yuan from the Muping District Finance Bureau of Yantai City.
Dongcheng Pharmaceutical: Report for the third quarter of 2024
Yantai Dongcheng Biochemicals (002675.SZ): The net income for the first three quarters was 0.167 billion yuan, a decrease of 41.62% year-on-year.
Gelonghui October 28th, Yantai Dongcheng Biochemicals (002675.SZ) released the third quarter report for 2024, achieving revenue of 2.162 billion yuan in the first three quarters, a year-on-year decrease of 16.36%; net income attributable to the shareholders of the listed company was 0.167 billion yuan, a year-on-year decrease of 41.62%; net income attributable to the shareholders of the listed company excluding non-recurring gains and losses was 0.15 billion yuan, a year-on-year decrease of 40.04%; basic earnings per share were 0.2024 yuan.
Yantai Dongcheng Biochemicals (002675.SZ) released its performance for the first three quarters, with a net income of 0.167 billion yuan, a year-on-year decrease of 41.62%.
yantai dongcheng biochemicals (002675.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Individual Investors Are Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Biggest Owners and Were Hit After Market Cap Dropped CN¥404m
Yantai Dongcheng Biochemicals (002675.SZ): A new type of dual-target radioactive internal diagnostic drug approved for clinical trials.
Yantai Dongcheng Biochemicals (002675.SZ) announced that its wholly-owned subsidiary, Yantai Lan Na Cheng Biotechnology Co., Ltd. (referred to as...
Dongcheng Pharmaceutical: 2024 Semi-Annual Report
Dongcheng Pharmaceutical: 2024 Semi-Annual Report Summary
Yantai Dongcheng Biochemicals (002675.SZ) announced its performance for the first half of the year, with a net income of 0.112 billion yuan, a decrease of 39.35%.
Yantai Dongcheng Biochemicals (002675.SZ) released the 2024 interim report. During the reporting period, the company achieved revenue...
Yantai Dongcheng Biochemicals (002675.SZ): The net income in the first half of the year was 0.112 billion yuan, a year-on-year decrease of 39.35%.
Yantai Dongcheng Biochemicals (002675.SZ) announced its semi-annual report for the year 2024, during which the company achieved revenue of 1.421 billion yuan, a year-on-year decrease of 20.41%; net income attributable to shareholders of the listed company was 0.112 billion yuan, a year-on-year decrease of 39.35%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.106 billion yuan, a year-on-year decrease of 39.02%; and basic earnings per share were 0.1356 yuan.
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Sheds CN¥396m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Yantai Dongcheng Biochemicals (002675.SZ): Its subsidiary, Lanna Cheng, has obtained the approval notice for drug clinical trials.
On August 2nd, Gelunhui announced that Yantai Dongcheng Biochemicals (referred to as "LanNacheng") a subsidiary of the company, received approval notice from the National Medical Products Administration regarding the clinical trial of 177Lu-LNC1011 injection. The company's research product, 177Lu-LNC1011 injection, is a targeted prostate-specific membrane antigen (Prostate Specific